Cost-effectiveness of peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin as initial treatment of chronic hepatitis C in Belgium
Wong, J. B.; Nevens, F.
Acta Gastro-Enterologica Belgica 65(2): 110-111
2002
ISSN/ISBN: 0741-6245 PMID: 12171051 Document Number: 543388
Document emailed within 1 workday
Related Documents
Nevens, F.; Van Vlierberghe, H.; D'Heygere, E.; Delwaide, J.; Adler, M.; Henrion, J.; Lenaerts, A.; Hendlisz, A.; Michielsen, P.; Bastens, B.; Brenard, R.; Laureys, A. 2010: A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients Acta Gastro-Enterologica Belgica 73(2): 223-228Khokhar, N. 2002: Effectiveness of 48 weeks Interferon alfa-2b in combination with ribavirin as initial treatment of chronic hepatitis Journal of Ayub Medical College Abbottabad: Jamc 14(3): 5-8
Hamidah, A.; Yong, J.F.; Zulkifli, H.I.; Jamal, R. 2002: Treatment of chronic hepatitis C virus infection with interferon alfa and ribavirin: sustained response in two patients with transfusion dependent thalassaemia Medical Journal of Malaysia 57(3): 353-356
Juszczyk, J.; Baka-Cwierz, B.; Beniowski, M.; Berak, H.; Bolewska, B.; Boroń-Kaczmarska, A.; Cianciara, J.; Cieśla, A.; Dziambor, A.; Gasiorowski, J.; Gietka, A.; Gliwińska, E.; Gładysz, A.; Gonciarz, Z.; Halota, W.; Horban, A.; Inglot, Młgorzata.; Janas-Skulina, U.; Janczewska-Kazek, E.; Jaskowska, J.; Jurczyk, K.; Knysz, B.; Kryczka, Wław.; Kuydowicz, J.; Lakomy, E.A.; Logiewa-Bazger, B.; Lyczak, A.; Mach, T.; Mazur, Włodzimierz.; Michalska, Z.; Modrzewska, R.; Nazzal, K.; Pabjan, Pł.; Piekarska, A.; Piszko, Pł.; Sikorska, K.; Szamotulska, K.; Sliwińska, M 2005: Pegylated interferon-alfa 2a with ribavirin in chronic viral hepatitis C (final report) Przeglad Epidemiologiczny 59(3): 651-660
Fernández, I.; Castellano, G.; Canga, F.; Colina, F.; García, H.; Fuertes, A.; Casis, B.; Martín, A.; Solís, J.A. 1995: A comparative randomized controlled study of the efficacy of interferon alfa-2b and interferon alfa-2a in the treatment of chronic hepatitis C Gastroenterologia y Hepatologia 18(2): 66-72
Mukherjee, S.; Lyden, E. 2006: Impact of pegylated interferon alfa-2a and ribavirin on hepatic fibrosis in liver transplant patients with recurrent hepatitis C: an open-label series Hepato-Gastroenterology 53(70): 561-565
Sood, A.; Midha, V.; Sood, N.; Bansal, M. 2006: Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 25(6): 283-285
Varghese, R.; Al-Khaldi, J.; Asker, H.; Fadili, A.A.; Al Ali, J.; Hassan, F.A. 2009: Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin Hepato-Gastroenterology 56(89): 218-222
Yu, J.; Liu, B.-w.; Lan, L.; Yuan, Y.; Zhang, H.; Jia, C.-h. 2010: Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 24(5): 373-375
Taskoparan, M.; Serin, E.; Gokturk, H.Savas.; Icer, M.Okan.; Abaci, K.; Ozer, B.; Zumrutdal, A.; Yilmaz, U. 2011: Early effect of peginterferon alpha-2b plus ribavirin treatment on blood pressure and insulin resistance in patients with chronic hepatitis C Hepato-Gastroenterology 58(107-108): 875-879
Ayyub, M.A.; El-Moursy, S.A.; Khazindar, A.M.; Abbas, F.A. 2009: Successful treatment of chronic hepatitis C virus infection with peginterferon alpha-2a and ribavirin in patients with sickle cell disease Saudi Medical Journal 30(5): 712-716
Roznovský, L.; Orságová, I.; Petrousová, L.; Mrázek, J.; Kloudová, A.; Kabieszová, L.; Kůrková, J.; Pospísek, M. 2010: Retreatment with peginterferon plus ribavirin in chronic hepatitis C patients: our own experiences Klinicka Mikrobiologie a Infekcni Lekarstvi 16(2): 73-75
Hrycewycz, N.; Sandres, K.; Barange, K.; Pascal, J.P.; Izopet, J.; Payen, J.L. 2001: Eradication of hepatitis C virus after 3 months of interferon and ribavirin treatment in an a interferon non-responder patient with chronic hepatitis C Gastroenterologie Clinique et Biologique 25(11): 1041-1042
2001: Treatment of chronic hepatitis B: interferon alfa first Prescrire International 10(51): 17-21
Nunnari, G.; Montineri, A.; Portelli, V.; Savalli, F.; Fatuzzo, F.; Cacopardo, B. 2012: The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C European Review for Medical and Pharmacological Sciences 16(8): 1013-1016
Muñoz, A.E. 2007: New strategies for a better use of peginterferon and ribavirin and new drugs with specifically-targeted antiviral therapy for chronic hepatitis C Acta Gastroenterologica Latinoamericana 37(2): 126-133
Cianciara, J.; Laskus, T.; Hryniewicz, H.; Jabłońska, J.; Loch, T. 1991: Treatment of chronic hepatitis B with interferon alfa-2b (Intron A) Przeglad Epidemiologiczny 45(4): 315-320
Bizid, S.; Ben Abdallah, H.; Kilani, I.; Mohamed, G.; Bouali, R.; Abdelli, N. 2013: Predictive factors of response to peginterferon and ribavirin in Tunisians patients with chronic hepatitis C: report of 141 cases La Tunisie Medicale 91(5): 327-331
Abramowicz, M. 2007: Peginterferon and ribavirin for hepatitis C New England Journal of Medicine 356(12): 1270-1271; Author Reply 1271
Castañeda, C.; García, E.; Grá, B.; Nodarse-Cuní, H.; García, W.; Andrade, M.; Martínez, G.; Trujillo, M.ía.; Soto, G.; Amoroto, M.é; Viada, C.; López-Saura, P. 2002: Interferon alfa 2b treatment decreases histological activity in children with chronic hepatitis B Acta Gastroenterologica Latinoamericana 32(1): 35-42